Delivery Order SPE2DB24D2018-SPE2DB25FWWM0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $4.5K delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors, with a completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a $3,544.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $15,167.73 to AmerisourceBergen Drug Corp for ZEPBOUND 5 mg/0.5 mL pen injectors on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price, non-set-aside award was issued under a competitive procurement process and represents a single delivery order transaction. The award is performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $81,521.82. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is due for completion by August 4, 2025, with performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $2,287.74. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award status. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWM0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a ceiling value of $10,513.23. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made without a set-aside designation through competitive procurement. Zepbound (tirzepatide) is a GLP-1 receptor agonist approved for chronic weight management and is supplied for use across military and federal healthcare systems. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen leverages its extensive supply chain capabilities to support military healthcare programs worldwide. The company's relationship with DLA spans a comprehensive portfolio of pharmaceutical and medical supply deliveries, enabling the agency to fulfill healthcare requirements across multiple therapeutic domains. This delivery order exemplifies AmerisourceBergen's role in the Defense Health Agency's pharmaceutical supply chain, supporting both active-duty military personnel and the broader federal healthcare infrastructure through the DLA's established procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/27/25 |